These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 32154886)

  • 1. Association of Disease Progression With Health-Related Quality of Life Among Adults With Breast, Lung, Pancreatic, and Colorectal Cancer.
    Marschner N; Zacharias S; Lordick F; Hegewisch-Becker S; Martens U; Welt A; Hagen V; Gleiber W; Bohnet S; Kruggel L; Dille S; Nusch A; Dörfel S; Decker T; Jänicke M
    JAMA Netw Open; 2020 Mar; 3(3):e200643. PubMed ID: 32154886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial.
    Twelves C; Cortés J; O'Shaughnessy J; Awada A; Perez EA; Im SA; Gómez-Pardo P; Schwartzberg LS; Diéras V; Yardley DA; Potter DA; Mailliez A; Moreno-Aspitia A; Ahn JS; Zhao C; Hoch U; Tagliaferri M; Hannah AL; Rugo HS
    Eur J Cancer; 2017 May; 76():205-215. PubMed ID: 28360015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality of life measures (EORTC QLQ-C30 and SF-36) as predictors of survival in palliative colorectal and lung cancer patients.
    Grande GE; Farquhar MC; Barclay SI; Todd CJ
    Palliat Support Care; 2009 Sep; 7(3):289-97. PubMed ID: 19788770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic factors and trajectory of HRQOL in patients with pancreatic cancer who received psychiatric intervention.
    Sugimoto H; Kawashima H; Ohno E; Hayashi D; Kuwahara T; Morishima T; Kawai M; Suhara H; Takeyama T; Yamamura T; Funasaka K; Nakamura M; Miyahara R; Watanabe O; Ishigami M; Suzuki M; Kimura H; Ozaki N; Hashimoto S; Goto H; Hirooka Y
    J Gastroenterol Hepatol; 2016 Mar; 31(3):685-90. PubMed ID: 26412310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry.
    Müller V; Nabieva N; Häberle L; Taran FA; Hartkopf AD; Volz B; Overkamp F; Brandl AL; Kolberg HC; Hadji P; Tesch H; Ettl J; Lux MP; Lüftner D; Belleville E; Fasching PA; Janni W; Beckmann MW; Wimberger P; Hielscher C; Fehm TN; Brucker SY; Wallwiener D; Schneeweiss A; Wallwiener M
    Breast; 2018 Feb; 37():154-160. PubMed ID: 29237546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health-related quality of life in early breast cancer.
    Groenvold M
    Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancer.
    Schwartzberg L; McIntyre K; Wilks S; Puhalla S; O'Shaughnessy J; Berrak E; He Y; Vahdat L
    BMC Cancer; 2019 Jun; 19(1):578. PubMed ID: 31195996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quality of Life in Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumors Receiving Peptide Receptor Radionuclide Therapy: Information from a Monitoring Program in Clinical Routine.
    Martini C; Buxbaum S; Rodrigues M; Nilica B; Scarpa L; Holzner B; Virgolini I; Gamper EM
    J Nucl Med; 2018 Oct; 59(10):1566-1573. PubMed ID: 30042164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health-related quality of life and disease symptoms in postmenopausal women with HR(+), HER2(-) advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy.
    Campone M; Beck JT; Gnant M; Neven P; Pritchard KI; Bachelot T; Provencher L; Rugo HS; Piccart M; Hortobagyi GN; Nunzi M; Heng DY; Baselga J; Komorowski A; Noguchi S; Horiguchi J; Bennett L; Ziemiecki R; Zhang J; Cahana A; Taran T; Sahmoud T; Burris HA
    Curr Med Res Opin; 2013 Nov; 29(11):1463-73. PubMed ID: 23962028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between anxiety disorders and domains of health related quality of life among Nigerians with breast cancer.
    Fatiregun OA; Olagunju AT; Erinfolami AR; Arogunmati OA; Fatiregun OA; Adeyemi JD
    Breast; 2017 Feb; 31():150-156. PubMed ID: 27866090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Observational Study to Assess Quality of Life in Patients with Pancreatic Neuroendocrine Tumors Receiving Treatment with Everolimus: The OBLIQUE Study (UK Phase IV Trial).
    Ramage JK; Punia P; Faluyi O; Frilling A; Meyer T; Saharan R; Valle JW
    Neuroendocrinology; 2019; 108(4):317-327. PubMed ID: 30699423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time to health-related quality of life score deterioration as a modality of longitudinal analysis for health-related quality of life studies in oncology: do we need RECIST for quality of life to achieve standardization?
    Anota A; Hamidou Z; Paget-Bailly S; Chibaudel B; Bascoul-Mollevi C; Auquier P; Westeel V; Fiteni F; Borg C; Bonnetain F
    Qual Life Res; 2015 Jan; 24(1):5-18. PubMed ID: 24277234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality of life of patients with metastatic pancreatic adenocarcinoma initiating first-line chemotherapy in routine practice.
    Laquente B; Macarulla T; Bugés C; Martín M; García C; Pericay C; Merino S; Visa L; Martín T; Pedraza M; Carnero B; Guardeño R; Verdaguer H; Mut A; Vilanova D; García A
    BMC Palliat Care; 2020 Jul; 19(1):103. PubMed ID: 32650765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality of life in a randomized trial of group psychosocial support in metastatic breast cancer: overall effects of the intervention and an exploration of missing data.
    Bordeleau L; Szalai JP; Ennis M; Leszcz M; Speca M; Sela R; Doll R; Chochinov HM; Navarro M; Arnold A; Pritchard KI; Bezjak A; Llewellyn-Thomas HA; Sawka CA; Goodwin PJ
    J Clin Oncol; 2003 May; 21(10):1944-51. PubMed ID: 12743147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality of life in metastatic pancreatic cancer patients receiving liposomal irinotecan plus 5-fluorouracil and leucovorin.
    Hubner RA; Cubillo A; Blanc JF; Melisi D; Von Hoff DD; Wang-Gillam A; Chen LT; Becker C; Mamlouk K; Belanger B; Yang Y; de Jong FA; Siveke JT
    Eur J Cancer; 2019 Jan; 106():24-33. PubMed ID: 30458340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
    Garassino MC; Gadgeel S; Esteban E; Felip E; Speranza G; Domine M; Hochmair MJ; Powell S; Cheng SY; Bischoff HG; Peled N; Reck M; Hui R; Garon EB; Boyer M; Wei Z; Burke T; Pietanza MC; Rodríguez-Abreu D
    Lancet Oncol; 2020 Mar; 21(3):387-397. PubMed ID: 32035514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
    Harrington KJ; Ferris RL; Blumenschein G; Colevas AD; Fayette J; Licitra L; Kasper S; Even C; Vokes EE; Worden F; Saba NF; Kiyota N; Haddad R; Tahara M; Grünwald V; Shaw JW; Monga M; Lynch M; Taylor F; DeRosa M; Morrissey L; Cocks K; Gillison ML; Guigay J
    Lancet Oncol; 2017 Aug; 18(8):1104-1115. PubMed ID: 28651929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health-related quality of life among breast, prostate, and colorectal cancer patients with end-stage disease.
    Färkkilä N; Torvinen S; Roine RP; Sintonen H; Hänninen J; Taari K; Saarto T
    Qual Life Res; 2014 May; 23(4):1387-94. PubMed ID: 24178630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters-patient-centered end points in trials of maintenance therapy.
    Friedlander M; Rau J; Lee CK; Meier W; Lesoin A; Kim JW; Poveda A; Buck M; Scambia G; Shimada M; Hilpert F; King MT; Debruyne P; Bologna A; Malander S; Monk BJ; Petru E; Calvert P; Herzog TJ; Barrett C; du Bois A
    Ann Oncol; 2018 Mar; 29(3):737-743. PubMed ID: 29267856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of illness beliefs and chemotherapy impact on quality of life in Japanese and Dutch patients with breast or lung cancer.
    van der Kloot WA; Uchida Y; Inoue K; Kobayashi K; Yamaoka K; Nortier HW; Kaptein AA
    Chin Clin Oncol; 2016 Feb; 5(1):3. PubMed ID: 26932427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.